HOME > Investors > Press Releases
2014-02-17
US FDA Grants Orphan-Drug Designation for ‘VM202-ALS’ for Treatment of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease)
2014-01-16
Progression of Business Plans in 2014
2014-01-16
Preliminary financial performance in 2013
2014-01-06
ViroMed Signs Co-Development Agreement with Reyon Pharmaceuticals to Develop VM202-ALS for Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease)
2013-06-18
Completes Patient Enrollment/Administration of VM202-DPN Phase II Clinical Study for the Treatment of Diabetic Peripheral Neuropathy
11 12 13 14 15 16 17 18 19 20